Evidence map›Paper›PMID 36980684›Full record

ReviewCancers2023

Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy.

Takeshi Hatanaka, Yutaka Yata, Atsushi Naganuma, Satoru Kakizaki

Open access · goldFull text readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Takeshi HatanakaDepartment of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi 371-0821, Japan.ORCID 0000-0003-3656-285X
Yutaka YataDepartment of Gastroenterology, Hanwa Memorial Hospital, Osaka 558-0041, Japan.
Atsushi NaganumaDepartment of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki 370-0829, Japan.ORCID 0000-0003-0663-0102
Satoru KakizakiDepartment of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki 370-0829, Japan.ORCID 0000-0003-0224-7093
National Hospital Organization Takasaki Medical Center · JPGunma Saiseikai Maebashi Hospital · JPHanwa Memorial Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transarterial chemoembolization (TACE) has been standard treatment for intermediate-stage hepatocellular carcinoma (HCC). However, all intermediate-stage HCC patients did not benefit from TACE treatment because intermediate-stage HCC encompasses a wide variety of HCCs. Owing to remarkable progress in systemic therapy, including molecular-targeted therapy for advanced-stage HCC, the standard treatment of HCC has recently shifted to systemic therapy. However, it remains controversial as to which treatment should be initially performed for intermediate-stage HCC. In addition, although curative treatment can be considered when the tumor shrinks, the timing of conversion therapy remains uncertain. This review summarizes the advances of HCC treatment and discusses treatment strategies for intermediate-stage HCC.

Indexed as

atezolizumab plus bevacizumabconversion therapydurvalumab plus tremelimumabhepatocellular carcinomaimmune checkpoint inhibitorintermediate-stage hepatocellular carcinomamolecular-targeted therapyTACE inappropriateTACE refractorytransarterial chemoembolizationtyrosine kinase inhibitorup-to-7 criteria

Identifiers

PMID36980684
PMCPMC10046825
OpenAlexW4327737540

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read30
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.